Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 28;8(9):15023-15033.
doi: 10.18632/oncotarget.14706.

Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China

Yongchun Zhou  1 , Yanlong Yang  2 , Chenggang Yang  3 , Yunlan Chen  4 , Changshao Yang  5 , Yaxi Du  5 , Guangqiang Zhao  2 , Yinjin Guo  5 , Lianhua Ye  2 , Yunchao Huang  1   2
Affiliations

Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China

Yongchun Zhou et al. Oncotarget. .

Abstract

To investigate the Epidermal Growth Factor Receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) in Yunnan province in southwestern China, we detected EGFR mutation by Amplification Refractory Mutation System (ARMS) polymerase chain reaction (PCR) using DNA samples from 447 pathologically confirmed NSCLC specimens (175 tissue, 256 plasma and 16 cytologic samples). The relationship between EGFR mutations and demographic and clinical factors were further explored. Subgroup analyses according to sample type (tissue and plasma) and histological type (adenocarcinoma) were done. We found the mutation rate was 34.9% in overall patients (42.3%, 29.7%, and 37.5% for tissue, plasma, and cytologic samples respectively). We found female (p < 0.0001), no smoking (p = 0.001), adenocarcinoma (p < 0.0001), and tissue specimen (p = 0.026) were associated with higher EGFR mutation rate. The most common mutations were exon 19 deletions (40%) and L858R point (30%) mutation. Interestingly, NSCLC patients from Xuanwei harbored a strikingly divergent mutational pattern for EGFR when compared with non-Xuanwei patients (higher G719X, G719X+S768I mutations, but lower 19 deletion and L858R mutations). Generally, EGFR mutation rate and pattern in Yunnan province was in accord with other Asian populations. However, Xuanwei subgroup showed strikingly divergent EGFR mutation spectrum from other general population. Our analysis also indicated that cftDNA analysis for EGFR mutations detection was feasibility for the patients lacking sufficient tissue for molecular analyses.

Keywords: EGFR mutation; Xuanwei; Yunnan; cftDNA; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

None.

Figures

Figure 1
Figure 1. The EGFR mutation spectrum in (A) Xuanwei population, (B) non-Xuanwei population, (C) overall population
NSCLC patients in Xuanwei had higher G719X, G719X+S768I, but lower 19 deletion and L858R mutations when compared with non-Xuanwei patients.
See this image and copyright information in PMC

References

    1. Chen W, Zheng R, Zeng H, Zhang S. The incidence and mortality of major cancers in China, 2012. Chin J Cancer. 2016;35:73. doi: 10.1186/s40880-016-0137-8. - DOI - PMC - PubMed
    1. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7. doi: 10.1200/JCO.2007.12.5435. - DOI - PubMed
    1. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727–40. doi: 10.1016/S0140-673662101-0. - DOI - PubMed
    1. Health Quality O. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser. 2010;10:1–48. doi: - PMC - PubMed
    1. The National Comprehensive Cancer Network NCCN Clinical PracticeGuidelines in Oncology: Non-small Cell Lung Cancer (version 4.2016) 2016 https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed January 12, 2016.

MeSH terms